Pharmacist interaction check before every oral cancer-drug prescription
Cancer pills interact with many common medicines for heart, stomach and blood conditions, sometimes dangerously. A pharmacist check before starting, and at each refill, would prevent avoidable harm.
Oral kinase inhibitors, CDK4/6 inhibitors, and hormonal agents have clinically significant interactions with proton pump inhibitors, anticoagulants, statins, and antiarrhythmics, and are increasingly prescribed to older multimorbid patients. Studies find potential interactions in a large proportion of such patients. A mandatory oncology pharmacist review at initiation and dose change, with a structured monitoring plan, would catch these systematically.
- Older and multimorbid patients are excluded and undertreated · Most people with cancer are over 65 but most trial patients are younger and fitter. We guess how to treat the majority.
- Toxicity and quality of life are undervalued · Trials measure how long people live, not how they live. Side-effects are under-reported and under-treated.
Pages like this
not linked directly; found by shared links- IdeaA standard handoff with medication reconciliation at every cancer care transition
Shares Older and multimorbid patients are excluded and undertreated, Toxicity and quality of life are undervalued.
- IdeaReport time toxicity, the days spent in healthcare, as a standard outcome for older patients
Shares Older and multimorbid patients are excluded and undertreated, Toxicity and quality of life are undervalued.
- IdeaDose adjustments driven by patients' own symptom reports, tested against clinician judgement
Shares Toxicity and quality of life are undervalued, Small-molecule kinase inhibitors.
- PairingCDK4/6 inhibitor + endocrine therapy
Shares Palbociclib, CDK4/6 inhibitors.
- IdeaHospital-at-home for oncology: treating low-risk febrile neutropenia and dehydration at home
Shares Older and multimorbid patients are excluded and undertreated, Toxicity and quality of life are undervalued.
- InstitutionWilmot Cancer Institute, University of Rochester
Shares Older and multimorbid patients are excluded and undertreated, Toxicity and quality of life are undervalued.
- TermInhibitor
Shares Palbociclib, CDK4/6 inhibitors, Small-molecule kinase inhibitors.
- IdeaAnalyse and dose by sex: women get more toxicity from many cancer drugs at the same dose
Shares Toxicity and quality of life are undervalued, Small-molecule kinase inhibitors.